Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 6/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
| ▸ | MMP13 | P45452 | 1/20 | 0.44 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TUBB | P07437 | 1/20 | 0.43 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5010346 | 0.90 | PPARG (0.48) | PPARGTP53MAPTCYP1A2HPGD | |
| SCHEMBL5012232 | 0.88 | JAK2 (0.48) | PPARGCNR1MAPTCYP1A2CYP3A4 | |
| SCHEMBL5010776 | 0.88 | GAA (0.56) | PPARGCNR1CYP1A2CYP3A4HPGD | |
| SCHEMBL5010405 | 0.87 | PPARG (0.59) | PPARGMMP13HSP90AA1HSP90AB1ALDH1A1 | |
| SCHEMBL5009734 | 0.86 | CYP1A2 (0.47) | PPARGCNR1CYP1A2CYP3A4HPGD | |
| SCHEMBL5013596 | 0.86 | ALDH2 (0.50) | PPARGCYP1A2HPGDCYP2C19MMP13 | |
| SCHEMBL5012123 | 0.85 | HPGD (0.50) | PPARGTP53POLBMAPTHPGD | |
| SCHEMBL5008255 | 0.84 | TSHR (0.45) | PPARGCNR1CYP1A2CYP2C19MMP13 | |
| SCHEMBL5013581 | 0.84 | PPARG (0.55) | PPARGCYP1A2CYP2C19MMP13HSP90AA1 | |
| SCHEMBL5013503 | 0.84 | PPARG (0.50) | PPARGCYP1A2CYP2C19MMP13GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | PPARG 706/4885CNR1 2091/4885TP53 3885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.